SUPERNUS PHARMACEUTICALS, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount of $1.33 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-28.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpense · last filed 2020-02-28
- SUPERNUS PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2019 was $1.33M.
- SUPERNUS PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2018 was -$2.20M.
- SUPERNUS PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2017 was -$2.31M, a 423.22% decline from fiscal 2016.
- SUPERNUS PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2016 was $715.00K, a 18.97% increase from fiscal 2015.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount 12 month |
|---|---|
| 2019-12-31 | $1.33M 10-K · filed 2020-02-28 |
| 2018-12-31 | -$2.20M 10-K · filed 2020-02-28 |
| 2017-12-31 | -$2.31M 10-K · filed 2020-02-28 |
| 2016-12-31 | $715.00K 10-K · filed 2019-03-01 |
| 2015-12-31 | $601.00K 10-K · filed 2018-03-01 |
| 2014-12-31 | $610.00K 10-K · filed 2017-03-16 |
| 2013-12-31 | $340.00K 10-K/A · filed 2017-01-20 |
| 2012-12-31 | $396.00K 10-K · filed 2015-03-12 |
| 2011-12-31 | $57.00K 10-K · filed 2014-03-21 |
| 2010-12-31 | $61.00K 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |